Literature DB >> 16680409

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.

Tobias Banaschewski1, David Coghill, Paramala Santosh, Alessandro Zuddas, Philip Asherson, Jan Buitelaar, Marina Danckaerts, Manfred Döpfner, Stephen V Faraone, Aribert Rothenberger, Joseph Sergeant, Hans-Christoph Steinhausen, Edmund J S Sonuga-Barke, Eric Taylor.   

Abstract

A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16680409     DOI: 10.1007/s00787-006-0549-0

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  60 in total

Review 1.  Obsessive compulsive disorder.

Authors:  G Mustafa Soomro
Journal:  Clin Evid       Date:  2002-06

2.  Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate.

Authors:  S H Kollins; C R Rush; P J Pazzaglia; J A Ali
Journal:  Exp Clin Psychopharmacol       Date:  1998-11       Impact factor: 3.157

Review 3.  Attention-deficit/hyperactivity disorder in adults: an overview.

Authors:  S V Faraone; J Biederman; T Spencer; T Wilens; L J Seidman; E Mick; A E Doyle
Journal:  Biol Psychiatry       Date:  2000-07-01       Impact factor: 13.382

4.  Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study.

Authors:  P Rasmussen; C Gillberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-11       Impact factor: 8.829

5.  A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Authors:  Laurence L Greenhill; Robert L Findling; James M Swanson
Journal:  Pediatrics       Date:  2002-03       Impact factor: 7.124

6.  Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.

Authors:  Joseph Biederman; Declan Quinn; Margaret Weiss; Sabri Markabi; Meredith Weidenman; Kathryn Edson; Goeril Karlsson; Harald Pohlmann; Sharon Wigal
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

7.  The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder.

Authors:  Louis S Matza; Anne M Rentz; Kristina Secnik; Andrine R Swensen; Dennis A Revicki; David Michelson; Thomas Spencer; Jeffrey H Newcorn; Christopher J Kratochvil
Journal:  J Dev Behav Pediatr       Date:  2004-06       Impact factor: 2.225

8.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

9.  Comparing the efficacy of medications for ADHD using meta-analysis.

Authors:  Stephen V Faraone; Joseph Biederman; Thomas J Spencer; Megan Aleardi
Journal:  MedGenMed       Date:  2006-10-05

10.  Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.

Authors:  Edmund J S Sonuga-Barke; James M Swanson; David Coghill; Heleen H DeCory; Simon J Hatch
Journal:  BMC Psychiatry       Date:  2004-09-30       Impact factor: 3.630

View more
  128 in total

1.  Stimulant ADHD medication and risk for substance abuse.

Authors:  Zheng Chang; Paul Lichtenstein; Linda Halldner; Brian D'Onofrio; Eva Serlachius; Seena Fazel; Niklas Långström; Henrik Larsson
Journal:  J Child Psychol Psychiatry       Date:  2013-10-25       Impact factor: 8.982

2.  Analysis of patients' preferences: direct assessment and discrete-choice experiment in therapy of adults with attention-deficit hyperactivity disorder.

Authors:  Axel C Mühlbacher; Matthias Nübling
Journal:  Patient       Date:  2010-12-01       Impact factor: 3.883

3.  Naturalistic-observational studies in the framework of ADHD health care.

Authors:  A Rothenberger; D Coghill; M Döpfner; B Falissard; H C Steinhausen
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-12       Impact factor: 4.785

4.  Chronic methylphenidate administration alters antioxidant defenses and butyrylcholinesterase activity in blood of juvenile rats.

Authors:  Felipe Schmitz; Emilene Barros da Silva Scherer; Maira Jaqueline da Cunha; Aline Andrea da Cunha; Daniela Delwing Lima; Débora Delwing; Carlos Alexandre Netto; Angela Terezinha de Souza Wyse
Journal:  Mol Cell Biochem       Date:  2011-10-20       Impact factor: 3.396

5.  Psychopathological profile in children with chronic tic disorder and co-existing ADHD: additive effects.

Authors:  Veit Roessner; Andreas Becker; Tobias Banaschewski; Aribert Rothenberger
Journal:  J Abnorm Child Psychol       Date:  2006-12-15

Review 6.  [Legal aspects of hyperkinetic disorders/ADHD].

Authors:  F Hässler; O Reis; J Buchmann; S Bohne-Suraj
Journal:  Nervenarzt       Date:  2008-07       Impact factor: 1.214

7.  Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder.

Authors:  Fariba Arabgol; Leily Panaghi; Paria Hebrani
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-06-18       Impact factor: 4.785

Review 8.  Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis.

Authors:  Hui Liu; Wenjing Feng; Dongfeng Zhang
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-08-24       Impact factor: 4.785

9.  Neuropharmacological effect of methylphenidate on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopy.

Authors:  Masako Nagashima; Yukifumi Monden; Ippeita Dan; Haruka Dan; Daisuke Tsuzuki; Tsutomu Mizutani; Yasushi Kyutoku; Yuji Gunji; Mariko Y Momoi; Eiju Watanabe; Takanori Yamagata
Journal:  Neurophotonics       Date:  2014-05-28       Impact factor: 3.593

10.  Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Authors:  Jan K Buitelaar; J Antoni Ramos-Quiroga; Miguel Casas; J J Sandra Kooij; Asko Niemelä; Eric Konofal; Joachim Dejonckheere; Bradford H Challis; Rossella Medori
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.